Search: onr:"swepub:oai:DiVA.org:uu-371540" >
Myeloablative vs re...
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
-
- Chhabra, Saurabh (author)
- Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA
-
- Ahn, Kwang Woo (author)
- Med Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
-
- Hu, Zhen-Huan (author)
- Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
-
show more...
-
- Jain, Sandeep (author)
- Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA
-
- Assal, Amer (author)
- Columbia Univ, Med Ctr, New York, NY USA
-
- Cerny, Jan (author)
- UMass Mem Med Ctr, Worcester, MA USA
-
- Copelan, Edward A. (author)
- Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
-
- Daly, Andrew (author)
- Tom Baker Canc Clin, Calgary, AB, Canada
-
- DeFilipp, Zachariah (author)
- Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA
-
- Gadalla, Shahinaz M. (author)
- NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA
-
- Gale, Robert Peter (author)
- Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England
-
- Ganguly, Siddhartha (author)
- Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA
-
- Hamilton, Betty K. (author)
- Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
-
- Hildebrandt, Gerhard Carl (author)
- Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
-
- Hsu, Jack W. (author)
- Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA;Univ Florida, Gainesville, FL USA
-
- Inamoto, Yoshihiro (author)
- Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan
-
- Kanate, Abraham S. (author)
- West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
-
- Khoury, H. Jean (author)
- Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
-
- Lazarus, Hillard M. (author)
- Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA
-
- Litzow, Mark R. (author)
- Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA
-
- Nathan, Sunita (author)
- Rush Univ, Med Ctr, Chicago, IL 60612 USA
-
- Olsson, Richard (author)
- Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden
-
- Pawarode, Attaphol (author)
- Univ Michigan, Dept Internal Med, Div Hematol Oncol, Med Sch,Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA
-
- Ringden, Olle (author)
- Karolinska Institutet
-
- Rowe, Jacob M. (author)
- Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel
-
- Saad, Ayman (author)
- Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
-
- Savani, Bipin N. (author)
- Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA
-
- Schouten, Harry C. (author)
- Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands
-
- Seo, Sachiko (author)
- Natl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan
-
- Shah, Nirav N. (author)
- Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA
-
- Solh, Melhem (author)
- Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA
-
- Stuart, Robert K. (author)
- Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA
-
- Ustun, Celalettin (author)
- Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
-
- Woolfrey, Ann E. (author)
- Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
-
- Yared, Jean A. (author)
- Univ Maryland, Greenebaum Canc Ctr, Div Hematol Oncol, Blood & Marrow Transplantat Program,Dept Med, Baltimore, MD 21201 USA
-
- Alyea, Edwin P. (author)
- Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA
-
- Kalaycio, Matt E. (author)
- Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
-
- Popat, Uday (author)
- Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
-
- Sobecks, Ronald M. (author)
- Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
-
- Saber, Wael (author)
- Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
-
show less...
-
(creator_code:org_t)
- 2018-11-05
- 2018
- English.
-
In: Blood Advances. - : American Society of Hematology. - 2473-9529 .- 2473-9537. ; 2:21, s. 2922-2936
- Related links:
-
https://europepmc.or...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Chhabra, Saurabh
-
Ahn, Kwang Woo
-
Hu, Zhen-Huan
-
Jain, Sandeep
-
Assal, Amer
-
Cerny, Jan
-
show more...
-
Copelan, Edward ...
-
Daly, Andrew
-
DeFilipp, Zachar ...
-
Gadalla, Shahina ...
-
Gale, Robert Pet ...
-
Ganguly, Siddhar ...
-
Hamilton, Betty ...
-
Hildebrandt, Ger ...
-
Hsu, Jack W.
-
Inamoto, Yoshihi ...
-
Kanate, Abraham ...
-
Khoury, H. Jean
-
Lazarus, Hillard ...
-
Litzow, Mark R.
-
Nathan, Sunita
-
Olsson, Richard
-
Pawarode, Attaph ...
-
Ringden, Olle
-
Rowe, Jacob M.
-
Saad, Ayman
-
Savani, Bipin N.
-
Schouten, Harry ...
-
Seo, Sachiko
-
Shah, Nirav N.
-
Solh, Melhem
-
Stuart, Robert K ...
-
Ustun, Celaletti ...
-
Woolfrey, Ann E.
-
Yared, Jean A.
-
Alyea, Edwin P.
-
Kalaycio, Matt E ...
-
Popat, Uday
-
Sobecks, Ronald ...
-
Saber, Wael
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood Advances
- By the university
-
Uppsala University
-
Karolinska Institutet